Emerging Industry Overview: Super Drugs
One of the most significant problems facing the health care and scientific communities is the continuous challenge of diseases becoming resistant to the drugs designed to cure them, especially for serious gram-positive infections. In developing countries, malaria and tuberculosis continues to devastate populations as they developed resistance to current drugs. HIV/AIDS continued its rampage, particularly in Africa, and other major infectious diseases, including cholera, e.coli, and malaria, ravaged poorer nations where the conditions and infrastructure to stem the tide were not in place. Moreover, in a rapidly globalized world, industrialized countries can no longer rest easy in the knowledge that such diseases will remain confined to the world's most downtrodden. For example, a drug-resistant staphylococcus called MRSA (methicillin-resistant Staphylococcus aureus) began to spread in epidemic quantities. Although most people affected were hospitalized patients with weak immune systems, the disease, which is transferred through skin contact, had spread to public places as well, including schools. Even though a majority of the infections are minor, according to CNN Money, thousands of Americans have died from MRSA.